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Abstract
Background: The active form of Vitamin D, 1,25-dihydroxyvitamin D3 (1,25D), has strong anti-
proliferative effects, yet the molecular mechanisms underneath this effect remain unclear. In
contrast, the molecular mechanism of 1,25D for the regulation of calcium homeostasis has
principally been resolved, demonstrating a pivotal role for the vitamin D receptor (VDR).
Results: We first addressed the question whether the anti-proliferative effects of 1,25D are
influenced by VDR. Knockdown of VDR by siRNA did not affect the anti-proliferative effects of
1,25D in MCF7 breast cancer cells. This unanticipated finding led us to take an alternative approach
using genome wide screens to study the molecular mechanisms of 1,25D in proliferation. For that
purpose, four independently developed and stable 1,25D resistant MCF7 cell lines were analyzed.
Array CGH identified a copy number alteration in a region of 13.5 Mb at chromosome 11q13.4-
14.1 common to all four 1,25D resistant cell lines. Expression arrays revealed that no single gene
was differentially expressed between the sensitive and resistant cells, but multiple membrane
receptor signaling pathways were altered in the 1,25D resistant cell lines. Importantly, in the
genome wide experiments neither VDR, CYP24A1 nor other known vitamin D signaling pathway
genes were associated with 1,25D resistance.
Conclusion: In conclusion, siRNA and genome wide studies both suggest that the anti-
proliferative effects of 1,25D in MCF7 breast tumor cell lines do not rely on classical Vitamin D
pathway per se.
Background
Strong anti-proliferative effects of 1,25-dihydroxyvitamin
D3 (1,25D) have been demonstrated in a wide spectrum
of solid cancers, in vitro and in animal models [1]. A link
between 1,25D status and cancer has also been demon-
strated in epidemiological studies. Together these data
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1,25D or synthetic analogs [2]. Yet, the molecular mecha-
nisms by which the 1,25D pathway exerts its anti-prolifer-
ative effects remain unclear. There is much need for
detailed knowledge of the molecular mechanism behind
the anti-proliferative action of 1,25D, since calcemic side-
effects form a major obstacle for the development of
1,25D or derivative drugs. Classically, 1,25D mediates the
maintenance of calcium homeostasis through activation
of the vitamin D receptor (VDR), a ligand dependent tran-
scription factor. The 1,25D-VDR receptor-ligand complex
functions by interacting with vitamin D response ele-
ments (VDREs) present in the promoter region of respon-
sive genes. While many known VDRE-containing genes
contribute to calcium regulation (e.g. CYP24A1, osteocal-
cin and osteopontin), others are involved in cellular proc-
esses like proliferation and apoptosis (e.g. p21, c-fos, and
Bcl2) [2-4]. Alternative, non-genomic pathways have been
suggested to explain the anti-proliferative action of 1,25D.
For example a membrane bound VDR was proposed [5]
and other forms of signaling outside the nucleus [6].
In previous years, several MCF7 cell lines have been gen-
erated of which proliferation is not affected by 1,25D.
Their 1,25D resistance was introduced by long time low
dose or increasing dose of 1,25D [7,8]. Notably, even
when cultured in the absence of 1,25D these cell lines still
persist to proliferate whenever exposed to 1,25D. This
makes it reasonable to assume that the alterations that led
to the resistance need to be (epi-)genetically fixed (chro-
mosomal copy number alterations [CNAs], point-muta-
tions, methylation). We therefore hypothesized that
genome wide screens could potentially identify these (epi-
)genetic changes in the absence of Vitamin D. In this study
we thus utilized genome wide approaches to identify
these stable alterations.
Our understanding that stable changes exist in these cell
lines which underlie their response to 1,25D, prompted
us to avoid the use of 1,25D. To perform this genomics
study in the presence of 1,25D would identify the massive
number of 1,25D downstream genes involved in prolifer-
ation and cell cycle. Indeed, there are various examples in
the literature where 1,25D has been used resulting in the
identification of such genes [9-13]. Although causative/
driver genes may have been identified in these studies,
they would be difficult to pinpoint within the massive
amount of proliferative genes. Thus, omission of 1,25D in
our genomic screens could potentially identify the causa-
tive/driver alterations that cause resistance in our model,
whilst omitting the detection of downstream proliferative
genes. Prior to these experiments we performed VDR
knockdown experiments to study the role of this receptor
in 1,25D anti-proliferation effect.
These experiments suggest that the anti-proliferative
effects of 1,25D can either be dissociated or only require
extremely low levels of the VDR in MCF7. In addition we
found that structural changes on chromosome 11q13.4-
14.1 may be involved in 1,25D resistance of MCF7.
Methods
Biological material
Four MCF7 breast tumor cell lines and their 1,25D resist-
ant counterparts were obtained and designated, MCF7wt1-
MCF7 VDR[7], MCF7wt2-MCF7 DR, MCF7wt2-MCF7 DRA
and MCF7wt3-MCF7 D3res [8]. The MCF7 VDR resistant
line was obtained by exposure to increasing amounts of
1,25D (0.01-10 μM), whereas MCF7 DR, MCF7 DRA and
MCF7 D3res were exposed to maximal concentrations of
100 nM 1,25D for up to 12 months. All cell lines were
maintained in Dulbecco's modified Eagle's medium (Inv-
itrogen, Leek, The Netherlands), supplemented with 10%
fetal bovine serum (Invitrogen), 2 mM glutamine, 100 U/
l penicillin and 100 U/l streptomycin and were cultured at
37°C in a humid atmosphere consisting of 5% CO2 and
95% air. Cell proliferation was measured by the 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bro-
mide (MTT) assay [14] (Sigma-Aldrich, Sintra, Portugal)
in the presence of 1,25D 100 nM or vehicle for 72 h.
VDR knockdown by siRNA
Knockdown of VDR expression was performed on all
three separate parental MCF7 cell lines as biological trip-
licates using the Silencer® Validated siRNA ID 4010
according to the manufacturer's protocols (Ambion Ltd.,
Huntingdon, United Kingdom). A 21-nucleotide probe
(5'-GGAGUUCAUUCUGACAGAUtt-3'), directed against
a sequence in exon 4 of the human VDR gene (accession
number NM_001017535), was transfected into all three
MCF7 parental cell lines using the siPORT™ Amine Trans-
fection Agent (Ambion). Transfection optimization and
efficiency was measured using the KDalert GAPDH Assay
Kit (Ambion), which measures GAPDH siRNA-induced
gene knockdown at the protein level. The efficiency level
obtained was within the levels described and according to
the manufacturer. The conditions used for optimal silenc-
ing were: 20.000 cells/well in 24-well plates, 20 nM of
dsRNA and 2 μl of the transfection agent. A negative
siRNA (Ambion) with no significant homology to any
known gene sequence was used as a control. Transient
transfections were performed for 72 h in the absence/pres-
ence of 100 nM 1,25D. After this period, the efficacy of
VDR knockdown was assessed by Q-PCR (using the prim-
ers described in Table 1) and proliferation by MTT assays.
Western blot and antibodies
Protein lysates were made of cells at approximately 70-
80% confluency. Cells were washed twice with PBS, lysed
on ice [1% (v/v) Triton X-100 and 1% (v/v) NP-40 inPage 2 of 11
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vortexed and clarified by centrifugation at 14000 × rpm
for 10 min at 4°C. Protein concentration was determined
using Dc protein assay (Bio-Rad, Amadora, Portugal). A
total of 50 μg of total protein lysates were analyzed by 8%
SDS-polyacrylamide gel electrophoresis and transferred to
a Amersham Hybond ECL nitrocellulose membrane (GE
Healthcare, Carnaxide, Portugal), using a Trans-Blot SD
Semi-Dry Transfer Cell (Bio-Rad). Membranes were
probed with the antibodies against VDR (GR37 Calbio-
chem, VWR, Carnaxide, Portugal) and α-tubulin (T6199
Sigma Aldrich). Quenching and immunostaining of the
blots was done according to the manufacturer's instruc-
tions. Detection was done using Amersham ECL Western
Blotting Detection Reagents (GE Healthcare). Immunob-
lots were performed at least three times, and representa-
tive figures are shown. The BioRad Quantity One 1-D
Analysis Software (Bio-Rad) was used to quantify the
band intensities.
Nucleic acid extractions
Cell lines were cultured in 75 cm2 flasks to 70-80% con-
fluency and harvested using 1 ml/10 cm2 of TRIzol reagent
(Invitrogen). Both RNA and DNA were extracted with TRI-
zol reagent according to the manufacturers' protocols.
Nucleic acids were quantified using a NanoDrop ND-
1000 (NanoDrop Technologies, Wilmington, USA) and
quality was visually confirmed by gel electrophoresis.
Microarray experiments
Arrays and data acquisition
For expression, NMD and CGH arrays hybridizations were
performed onto slides containing 60-mer oligonucle-
otides representing 26845 unique genes based on The
Human Release 2.0 oligonucleotide library as designed by
Compugen (San Jose, California, USA), and obtained
from Sigma-Genosys [15]. Following hybridization using
a HybArray 12 (Perkin-Elmer, Zaventem, Belgium) the
slides were scanned with a Microarray Scanner G2505B
(Agilent Technologies Netherlands B.V., Amstelveen, The
Netherlands). Spot analysis and quality control were fully
automated using BlueFuse version 3.2 (BlueGnome,
Cambridge, UK) and spots with quality flag <1 or confi-
dence value < 0.1 were excluded from further analysis.
Original data files for all arrays can be found in GEO
(http://www.ncbi.nlm.nih.gov/geo/; accession numbers -
GSE9867, GSE9887 and GSE9959).
Expression microarrays and analysis
A total of 14 microarray expression experiments were car-
ried out, with four biological replicates and 10 technical
replicates including dye swaps. cDNA probes were gener-
ated from 30 μg of total RNA, and experiments performed
as previously described [16]. After scanning and data
acquisition, genes with spots flagged in more than one
array were excluded for further analysis. For the remaining
genes, the value of a flagged spot was imputed using K
nearest neighbors' imputation as implemented in the R-
package "impute". Curvature in the MA plots was limited
but nevertheless normalized using Lowess as imple-
mented in the R-package "MAAnova" [17]. Using an anal-
ysis of variance (ANOVA) model, "dye", "hybridization
date" and "sample" were specified as factors together with
the factor of interest, "treatment" ("parental" minus
"resistant"). MAAnova was used to perform ANOVA for
all genes. Permutations were applied to the sample labels
and uncorrected pooled p-values from the F-statistics were
computed for the treatment effect. FDR corrected p-values
were computed to adjust for multiple testing. PANTHER
Classification System was used to statistically determine
over- or under- representation of pathways http://
www.pantherdb.org/[18].
Table 1: List of primers used for Q-PCR experiments
Primers 5' → 3'
Gene
symbol
Accession number
[GenBank:]
Forward Reverse
FAM14A NM_032036 GCCTCTGTTGGGTCAGTGTTG TCATCTTCTTTAGCCTCGGGTT
CYP24A1 NM_000782 GACTACCGCAAAGAAGGCTAC CATCACTTCCCCTGGTTTCATTA
PHLDA1 NM_007350 TGAAGGAGGGCGTGCTGG GCTGCTTGGGCGGGATAA
DDIT4 NM_019058 GGACGCACTTGTCTTAGCAGTTCTC CCAGGGCGTTGCTGATGAA
CYFIP2 NM_014376 CATTCCGTATCCACCGTCCAA GCTGGGTAATGAGTCTGTTCAAGTC
FOXC1 NM_001453 CACTCGGTGCGGGAGATGTT GAGACTGGCTGGAAGGGAAGG
CRABP2 NM_001878 ACAGGAGGGAGACACTTTCTACATCAA TCCCATTTCACCAGGCTCTTACA
ST6GALNAC5 NM_030965 GCCACTGGACGGATACCTCG CTGGGAGCCTTGCCGACT
NUAK1 NM_014840 TGAAGAAGCGAAGCAACAGCG GAGGGTAAGGCAGGACCAACTA
VDR NM_000376 AGCGGAAGGCACTATTCACC CATCATGCCGATGTCCACACA
GAPDH NM_002046 TGAAGCAGGCGTCGGAGGG CGTCAAAGGTGGAGGAGTGGGTPage 3 of 11
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Cells were incubated with the drug Emetine (Fluka),
which inhibits the NMD pathway, hereby blocking the
degradation of non-sense mRNAs [19]. Approximately 4 ×
106 cells at 70%-80% confluence were treated with 100
μg/ml emetine for 10 hours [19]. Following incubation
with emetine, cells were directly lyzed by the addition of
TRIzol (Invitrogen) omitting any treatment with Actino-
mycin D. In total four hybridizations were performed
(four biological replicates), one for each of the paired
(MCF7 resistant vs. MCF7) emetine treated cell lines. For
this reason the inclusion of a control experiments consist-
ing of "normal" keratinocytes as suggested [19] was
unnecessary and therefore omitted in the study. After
scanning and data acquisition, spots flagged were
excluded for further analysis and a distribution curve was
built with the log2 ratios for the remaining genes. In typi-
cal conditions a normal distribution of the ratios is
expected. By blocking the degradation of nonsense
mRNAs an accumulation of genes with mutations is
expected, which can be measured by a "skew" in the "nor-
mal" distribution plot towards the positive side.
Array comparative genomic hybridization (array CGH) and analysis
CGH arrays were performed as previously described [15].
DNA from resistant and sensitive cell lines were differen-
tially labeled and co-hybridized. For interpretation and
visualization purposes, smoothing was performed using
"aCGH-Smooth" [20], with lambda set to 3.0. Smoothed
log2 ratios of -0.15 and 0.15 were used as thresholds to
define gains and losses.
Quantitative PCR (Q-PCR) confirmation of siRNA and 
expression arrays
Gene expression was technically confirmed by Q-PCR
using SYBR green chemistry. Non-redundant primers were
designed and are listed in Table 1. Primer pairs were
checked for linear response over a range of cDNA input
and for nonspecific targets with dissociation curves. Total
RNA (360 ng) was reverse-transcribed to cDNA according
to the manufacturer's instructions (Multi-Scribe Reverse
Transcriptase, Applied Biosystems, Nieuwerkerk aan den
IJssel, The Netherlands) and subsequently used in the
amplification with 10 μM gene specific primers and 12.5
μl of 2× SYBR green master mix (Applied Biosystems) in a
total reaction volume of 25 μl. Reactions were carried out
using standard cycle parameters on an ABI PRISM
Sequence 7700 Detection System (Applied Biosystems).
Relative transcript levels were determined using GAPDH
as an internal reference. Statistically significant differences
between resistant and sensitive cell lines were determined
using comparative delta-delta Ct test [21]. All reactions
were done in triplicate and expressed as mean of the val-
ues from three separate experiments.
In silico analysis of array CGH profiles from solid breast 
tumors
Publicly available array CGH datasets were analyzed for
the presence of alterations in the region 11q13.4-14.1. A
total of four datasets corresponding to 356 individual pro-
files were screened [22-25]. The datasets were obtained
from publicly available databases (GEO accession num-
bers: GSE8757 freeze March 2006, GSE6448 freeze May
2004 and ArrayExpress: E-TABM-170 freeze July 2003)
and the journal website (http://www.pnas.org/content/
99/20/12963/suppl/DC1, freeze October 2000). The 356
profiles included 315 breast tumors and 41 breast tumor
cell lines. The CGHcall package [26] was used to identify
alterations in the 13.5 Mb region at chromosome 11.
Results
Proliferation in 1,25D resistant and sensitive MCF7 cell 
lines
VDR is essential for regulation of calcium homeostasis by
1,25D, but its role in the anti-tumor effects mediated by
vitamin D signaling remains unclear. Therefore, the objec-
tives of these studies were first, to determine whether VDR
knockdown would alter the anti-proliferative effects of
1,25D, and second, to identify genomic changes in stable
1,25D resistant cell lines. Studies were conducted with
several MCF7 breast tumor cell lines previously selected
for 1,25D resistance by independent laboratories [7,8].
We first confirmed the effects of 1,25D on growth of the
three parental MCF7 breast tumor cell lines and the four
variants selected for 1,25D resistance (Figure 1). In the
presence of 100 nM 1,25D, proliferation was reduced
approximately 50% in all parental MCF7 cell lines,
according to the MTT assay. In contrast, 1,25D had no
effect on proliferation in the resistant MCF7 cell lines.
These data are in agreement with previous observations
independently reported on these cell lines [7,8].
Effect of VDR knockdown on 1,25D mediated proliferation 
inhibition
Since VDR is pivotal in calcium metabolism we first tested
whether VDR expression is correlated with proliferation
and 1,25D sensitivity. For that reason, MCF7 cell lines
were transfected with either a specific VDR-siRNA or a
non-specific siRNA. The transfection in combination with
the MTT proliferation assay allowed us to assess the effect
of 1,25D on cells with reduced VDR expression. Surpris-
ingly, parental MCF7 cells transfected with VDR-siRNA
were growth inhibited by 100 nM 1,25D to the same mag-
nitude as cells transfected with negative siRNA (Figure
2A). The degree of VDR knockdown by the VDR-siRNA
was assessed in these cells at both the mRNA and protein
level. By Q-PCR, a strong reduction of VDR transcripts was
observed (Figure 2B and Additional file 1), and a compa-
rable decrease in VDR protein expression was detected on
western blots for VDR (Figure 2C and Additional file 1).Page 4 of 11
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effector gene CYP24A1 was downregulated. In cells
expressing negative siRNA, 100 nM 1,25D strongly (300-
fold) induced CYP24A1 expression whereas in cells
expressing VDR-siRNA this induction of CYP24A1 expres-
sion by 1,25D was not observed (Figure 2D). Besides
being a downstream effector gene containing a VDRE,
CYP24A1 is an important component of the 1,25D cal-
cium metabolism pathway. Our data thus demonstrate
that decreased VDR and CYP24A1 expression do not affect
cellular sensitivity to the anti-proliferative effects of
1,25D. While unexpected, these data may indicate that a
very low level of VDR expression is sufficient to trigger
1,25D mediated growth inhibition. Alternatively, 1,25D
may mediate growth regulation in MCF7 cells via non-
genomic processes [5,6,27].
Identification of differential gene expression between 
1,25D resistant and sensitive MCF7 cell lines
The siRNA results described above indicate that reduction
of VDR expression did not necessarily de-sensitize cells to
the anti-proliferative action of 1,25D. Consistent with the
concept that VDR signaling can be dissociated from
growth regulation, MCF7 cells selected for resistance to
1,25D retain VDR expression and function [7,8]. To assess
the molecular mechanism that is involved in dictating cel-
lular resistance to 1,25D, we performed genome wide
analysis at the RNA and DNA level with these 1,25D
resistant and sensitive MCF7 cell lines. These studies were
performed in the absence of 1,25D in order to identify
driver/causative alterations rather than 1,25D down-
stream genes involved in proliferation and cell cycle as
described in the introduction. RNA isolated from all four
1,25D resistant cell lines was hybridized directly to their
sensitive MCF7 counterparts. Both technical as well as
biological replicates were combined in the analysis (in
total 14 hybridizations). Using MAAnova, 1001 out of
26845 genes (3.7%) were differently expressed in 1,25D
resistant MCF7 cells compared to the parental lines (see
Additional file 2). The introduction of a Lowess normali-
zation step had little to no impact on the overall results.
When ranking the most significant differently expressed
genes with respect to their log2 ratios, it was observed that
no single gene was highly differentially expressed in rela-
tion to 1,25D resistance of all four cell lines. Instead,
many genes had small increases or decreases in expression
(Table 2 and Additional file 2). The differential expression
of key genes was technically validated and confirmed by
Q-PCR (Table 2), i. e. genes up-regulated in the array
experiments are up-regulated in the Q-PCR, vice versa for
down-regulated genes. Genes that were uniformly down
regulated in the 1,25D resistant sub-lines included
FAM14A, a poorly characterized interferon inducible
gene; PHLDA1, a pleckstrin homology domain-contain-
ing protein involved in apoptosis; and CYP24A1, which
codes for an enzyme that catabolizes 1,25D. Up-regulated
genes included SLITRK6 an integral membrane protein
generally expressed in neuronal cells; DDIT4, a stress
response gene that initiates apoptosis; and CYFIP2, a gene
involved in a redundant network of genes responsible for
p53-dependent apoptosis. Down regulation of CYP24A1
in the resistant cell lines was surprising, as up-regulation
of this gene has been linked to 1,25D resistance [28] and
CYP24A1 was found to be amplified in various human
tumors, including breast [29]. Consistent with previous
reports [7,8], the VDR itself was not identified as differen-
Effect of 100 nM 1,25D or vehicle for 72 h on proliferation in the MCF7 cell lines used in the present studyFigure 1
Effect of 100 nM 1,25D or vehicle for 72 h on proliferation in the MCF7 cell lines used in the present study. Data 
represents the mean ± SD of three values. Statistical significance was assessed by two-tailed unpaired Student's t-test. Differ-
ences were considered statistically significant when p < 0.01 (*). p > 0.01 was considered not significant (ns).Page 5 of 11
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sion arrays. Because VDR was flagged in the array analysis
due to low expression, we used Q-PCR analysis to confirm
that VDR expression was not differentially expressed
between resistant and sensitive cell lines.
VDR signaling pathway is not identified by expression 
arrays on the 1,25D resistant cell lines
Since neither VDR nor CYP24A1 were implicated in the
1,25D resistance of these MCF7 cell lines, we examined
whether other genes involved in the vitamin D pathway,
or alternative signaling pathways, might be involved. To
test this, we used pathway analysis to determine if the set
of 1001 genes differentially expressed between the sensi-
tive and resistant cell lines was enriched for genes serving
particular pathways. Screening more than 160 pathways
in PANTHER, six were found to be significantly altered in
the 1,25D resistant cell lines relative to their parental
counterparts. Notably, the VDR signaling pathway was
not identified by this approach. Instead, five of the six
Vitamin D receptor (VDR) knock down experiments through siRNAF gure 2
Vitamin D receptor (VDR) knock down experiments through siRNA. (A) MTT proliferation assay showing the effect 
of 100 nM 1,25D or vehicle after 72 h in cells transfected with a negative control siRNA (Neg-siRNA) and cells transfected 
with specific siRNA for VDR (VDR-siRNA). Results are expressed as % of control (Neg-siRNA transfected cells grown without 
exposure to 1,25D). (B) Q-PCR of VDR gene expression in cells transfected with neg-siRNA or VDR-siRNA normalized to 
GAPDH in the absence of 1,25D. (C) Western-blot for VDR and α-tubulin (loading control) in lysates from cells transfected 
with the negative siRNA or the VDR-siRNA. Band intensities are indicated below each lane. (D) Q-PCR of CYP24A1 gene 
expression in cells transfected with Neg-siRNA or VDR-siRNA. Data are mean ± SD of fold change in CYP24A1 expression in 
1,25D treated cells vs. vehicle treated control. Statistical significance was assessed by two-tailed unpaired Student's t-test. Dif-
ferences were considered statistically significant when p < 0.01 (*). p > 0.01 was considered not significant (ns).
 
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signaling pathways involved in the cellular response to
extracellular signals (Table 3): EGF, PDGF, FGF, Inter-
leukins and Toll receptor pathways. This analysis also
identified differential expression of genes in the B cell acti-
vation pathway in association with 1,25D resistance.
Interestingly, these six signaling pathways were over-rep-
resented in the 1,25D resistant cell lines, and all are
involved in the control of proliferation, cell growth and
apoptosis. The specific genes in these pathways that were
altered between sensitive and resistant cell lines are listed
in Table 4. Additional experiments are needed to assess
the involvement of these pathways in dictating cellular
sensitivity to 1,25D.
Nonsense mutations were not identified in 1,25D resistant 
cell lines
Nonsense mediated decay (NMD) analysis was performed
to identify genes that might have undergone mutational
events related to the 1,25D resistance phenotype. Resist-
ant and sensitive cell lines were treated with emetine to
block degradation of nonsense RNAs. Hybridizations
were performed of resistant vs. sensitive emetine treated
cell lines such that all 4 biological replicates were hybrid-
ized on a total of 4 arrays. The results indicated that no
genes were recurrent in the biological replicates. In addi-
tion, the top positive log2 ratio was similar to the top neg-
ative log2 ratio. Visualization of all log2 ratios further
revealed a normal distribution of the data around zero
with no gene that stood out to the positive side of the
curve. Thus, overall this data did not support the concept
that the 1,25D resistant cell lines shared one or more com-
mon mutated genes.
Resistant cell lines exhibit copy number reduction of 
chromosome 11q13.4-14.1
Chromosomal copy number aberrations (CNAs) affect
the properties of a cancer in a (sub-) type specific manner
Table 2: Selected list of genes associated with 1,25D resistance identified by expression array analysisa
Gene
symbol
Accession
Number
[GenBank:]
Gene description Chromosome
location
Expression array
(log2 ratio)
Q-PCR
Top 5 down-regulated
FAM14A NM_032036 Family with sequence similarity 14, member A 14q32.13 -2.03 -6.79
CYP24A1 NM_000782 Cytochrome P450 (Vitamin D 24-hydroxylase) 20q13 -1.20 -
PHLDA1 NM_007350 Pleckstrin homology-like domain, family A, member 1 12q15 -1.11 -3.69
ZFP276 NM_152287 Zinc finger protein 276 16q24.3 -1.02 -
- BF244871 cDNA clone IMAGE:4083158 11 -0.98 -
Top 5 up-regulated
SLITRK6 NM_032229 SLIT and NTRK-like family, member 6 13q31.1 0.98 -
BMP7 AK094784 Bone morphogenetic protein 7 20q13 0.96 -
- BG115630 cDNA clone IMAGE:4417140 4 0.95 -
DDIT4 NM_019058 DNA-damage-inducible transcript 4 10pter-q26.12 0.91 2.64
CYFIP2 NM_001037332 Cytoplasmic FMR1 interacting protein 2 5q33.3 0.89 1.98
Additionalb
FOXC1 NM_001453 Forkhead box C1 6p25 -0.80 -2.05
CRABP2 NM_001878 Cellular retinoic acid binding protein 2 1q21.3 -0.66 -2.69
ST6GALNAC5 NM_030965 GalNAc alpha-2,6-sialyltransferase V 1p31.1 -0.10 -0.39
NUAK1 NM_014840 NUAK family, SNF1-like kinase, 1 12q23.3 0.75 2.66
VDR NM_000376 Vitamin D receptor 12q13.11 - 0.13
-. Not available
a. Genes were identified considering FDR<0.05 as significant, with the exception of VDR due to flagging (see text for explanation)
b. Additional genes selected for Q-PCR quantification
Table 3: Pathways associated with 1,25D resistance identified using Panther Ontology gene enrichment analysis
Pathway Over/under representation FDR (<0.05)
B cell activation + 0.01
EGF receptor signaling pathway + 0.02
PDGF signaling pathway + 0.02
Interleukin signaling pathway + 0.03
FGF signaling pathway + 0.04
Toll receptor signaling pathway + 0.04
NOTE: + denotes over-representation in 1,25D resistant cellsPage 7 of 11
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losses and high level amplifications on multiple chromo-
somes were identified in MCF7 cell lines [31]. These chro-
mosomal changes can occur spontaneously during in vitro
culture or in response to environmental factors such as
drugs [32]. Therefore, in the current study we were inter-
ested to determine whether in vitro selection for 1,25D
resistance induced recurrent chromosomal alterations in
MCF7 cells. To monitor chromosomal aberrations array
CGH was performed. Direct hybridization of DNA from
sensitive and resistant cell lines yielded primarily flat pro-
files, with few regions showing copy number alteration.
As a control, the separate channels of these dual channel
CGH arrays were interchanged using a common reference
(across array) to verify the original MCF7 profiles [33]. Of
those regions that were altered between sensitive and
resistant cell lines, 76% showed reduction in copy
number, but only one region was commonly altered in all
four 1,25D resistant cell lines and none of the parental
counterparts (Figure 3). The altered region varied in size
with the smallest region of overlap (SRO) of 13.5 Mb and
ranges from 11q13.4 to 11q14.1. The region contains 80
known genes [34], none of which are known to be
involved in the vitamin D signaling pathway. We hypoth-
esized that if loss of vitamin D responsiveness contributes
to human malignancies, alterations in chromosome
11q13.4-14.1 might also be frequent in solid tumors.
Publicly available array CGH datasets were used to screen
for alterations at 11q13.4 to 11q14.1 in breast tumors.
This in silico analysis showed that 40.6% of the breast
tumors and 41% of the breast tumor cell lines exhibited
alterations in this particular region of chromosome 11.
Table 4: Genes present in at least three of the significant pathways identified
Panther Ontology Pathway
Gene symbol Accession number
[GenBank:]
B cell EGFR PDFG Interleukin FGF Toll
PIK3CB NM_006219 + + + + +
GRB2 NM_002086 + + + + +
PLCG2 NM_002661 + + + +
SOS1 NM_005633 + + + + +
YSK4 NM_025052 + + + + +
MAPK9 NM_139068 + + + + +
MAP2K3 NM_002756 + + +
STAT5B NM_012448 + + +
RASAL2 NM_170692 + + +
NOTE: B cell activation; EGF receptor signaling pathway; PDGF signaling pathway; Interleukin signaling pathway; FGF signaling pathway; Toll 
receptor signaling pathway; + denotes involvement in the pathway.
Frequency plot for chromosomal alterations identified by array CGH with 1,25D resistant vs. sensitive MCF7 cell linesigur  3
Frequency plot for chromosomal alterations identified by array CGH with 1,25D resistant vs. sensitive MCF7 
cell lines. Alterations are ordered by chromosomal position and the y-axis indicates the number of cell line pairs in which the 
given alteration occurs. Green represents gains and red losses.Page 8 of 11
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The molecular mechanisms underlying the anti-prolifera-
tive effects of 1,25D are poorly understood, despite the
well known role of 1,25D in the regulation of calcium
homeostasis. In this study we show that the anti-prolifer-
ative effects of 1,25D may be functional in MCF7 breast
tumor cell lines, without a role for the central player in
calcium homeostasis, VDR. These results were unantici-
pated since several known regulators of cell growth, such
as p21 and GADD45A, contain functional VDREs in their
promoter region and are induced by the 1,25D-VDR com-
plex in cancer cells [35,36]. Furthermore, cell lines derived
from VDR knockout (KO) mice are resistant to 1,25D
mediated growth arrest [37], and re-introduction of VDR
into these cells restores sensitivity to 1,25D mediated
growth inhibition (Keith and Welsh, unpublished). While
additional studies are needed to determine whether resid-
ual VDR activity in the MCF7 cells expressing VDR-siRNA
is sufficient to mediate growth inhibitory signals upon
binding 1,25D, our data demonstrates that marked reduc-
tions (~90% at the transcript level and ~85% at the pro-
tein level) in VDR do not necessarily induce 1,25D
resistance. Seemingly contradictive to the role of VDR, this
finding is consistent with previous data from MCF7 sub-
lines selected in vitro for resistance to 1,25D, in which
VDR function is retained [7,8], indicating dissociation
between VDR expression and 1,25D mediated growth
inhibition.
In the light of these results, we hypothesized that driver/
causative genes other than VDR, or alternative pathways
unrelated to vitamin D calcium signaling might impact
1,25D sensitivity or replace its function. Therefore we
used genome wide screens to identify genetic alterations
that cause resistance in our model. Indeed, in all four
1,25D resistant cell lines one common chromosomal
region had reduced copy number at 11q13.4-14.1 (Figure
3). Eighty genes are present in this 13.5 Mb chromosomal
region, none of which could readily be assigned to 1,25D
mediated VDR signaling. In focally aberrant regions (<3
Mb) identification of driver genes is often straight for-
ward, but it is our experience [38], acknowledged by oth-
ers [39] that identification of candidate genes in larger
chromosomal regions is problematic. One effort made
was integration with our expression array data which did
not proof helpful; hence pathway analysis of genes in this
region would be arbitrary. Other authors performed simi-
lar array experiments in the presence of 1,25D, yet again
none of the 80 genes in this region was identified [9-13].
Our expression array analysis confirmed that 1,25D resist-
ant cells did not exhibit significant reductions in VDR
gene expression. Still, as described previously the VDR-
transcriptome may be significantly altered [12]. Indeed,
these authors showed that CYP24A1 was the only induced
gene that was common to the genetic profiles of the
parental and the 1,25D resistant cell lines when treated
with 1,25D treated [12]. In contrast, our expression array
analysis identified CYP24A1 as one of the top five down-
regulated genes in the 1,25D resistant MCF7 cell lines.
Since CYP24A1 is strongly regulated by 1,25D in a nega-
tive feed-back, but no 1,25D was present in our test, any
discussion on this apparent down-regulation remains
speculative.
Pathway analysis of the expression arrays did not identify
any other known vitamin D pathway genes either.
Instead, over-representation of multiple membrane recep-
tor signaling pathways known to be involved in the con-
trol of proliferation and apoptosis were associated with
the 1,25D resistant phenotype. The five membrane-
bound receptor signaling pathways identified in our anal-
ysis share the Grb2 and SOS genes and drive cell prolifer-
ation. Interestingly, previous analysis of one set of these
sub-lines indicated that, in the absence of 1,25D, the dou-
bling time of the MCF7 D3res cells was shorter than that
of the MCF7 sensitive cells from which they were derived
[8]. Furthermore, using proteomic approaches we previ-
ously identified several proteins in the MAPK-ERK-RAS
mitogenic pathway that were differentially expressed in
the MCF7 D3res cells relative to their sensitive MCF7
counterparts under basal conditions [9]. Although mech-
anisms have yet to be clarified, chronic up-regulation of
these mitogenic pathways may selectively disable VDR sig-
naling, leading to 1,25D resistance. In support of this
idea, RAS activation has been shown to induce 1,25D
resistance in keratinocytes via direct phosphorylation of
VDR [40].
In a previous study we used the same genome wide tools
to identify the mechanisms of Gemcitabine resistance
[32]. Results were simple and straightforward to interpret;
Gemcitabine had selected for tumor cells with high level
amplifications, leading to high expression levels of genes
within that amplicon which resulted in drug resistance
[32]. Here a similar simple mechanism for 1,25D resist-
ance was not identified. A possible explanation may be
that most therapeutic drugs (e.g. Gemcitabine) are syn-
thetic and 1,25D is generated endogenously. Conse-
quently, malignant cells would need to develop resistance
to the anti-proliferative effects of 1,25D in a very early
stage of their development to allow tumor expansion.
Accordingly, we hypothesized that many solid tumors
would also contain alterations at 11q13.4-14.1. Indeed,
screening of four datasets covering 358 individual array
CGH profiles showed that the region in chromosome
11q13.4-14.1 is highly unstable strengthening this
hypothesis.Page 9 of 11
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Evidence accumulates demonstrating an important role
for Vitamin D not only in the treatment but also in the
prevention of cancer, mainly breast cancer. Dozens of
vitamin D analogues have been developed by pharmaceu-
tical firms with the goal of dissociating the potentially
toxic calcemic actions of 1,25D from its anti-tumor
actions for use in cancer therapy. Because vitamin D ana-
logs are currently in approximately 20 clinical trials [2],
understanding the mechanisms by which 1,25D mediates
growth inhibition, as well as the basis for development of
1,25D resistance, is crucial. Our genome wide screening
analysis has identified chromosomal regions, membrane
receptor pathways and new candidate genes outside of the
classical VDR signaling pathway that may be associated
with 1,25D resistance. These data provide new avenues for
future explorations that may facilitate the development
and use of vitamin D based drugs for cancer and other
clinical applications.
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